Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SG3199 is a **synthetic pyrrolobenzodiazepine (PBD) dimer** engineered as a DNA minor groove cross-linking agent with **potent cytotoxicity** against a broad range of human solid tumor and hematological cancer cell lines. It acts by forming highly cytotoxic DNA interstrand cross-links that are non-distorting and evade normal DNA repair mechanisms. SG3199 is primarily used as the **released warhead component** of antibody-drug conjugate (ADC) payloads such as tesirine, which is incorporated into several experimental ADCs for targeted cancer therapy. The compound demonstrates high plasma protein binding across species (>90%), rapid cellular uptake, and a very short half-life upon intravenous administration, which helps minimize systemic toxicity. Its effectiveness is enhanced in tumor cells with defects in DNA repair mechanisms, and it is only moderately susceptible to common drug resistance mechanisms[1][5][10][13][16][18].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SG3199.